Karen Kaucic Net Worth

The estimated Net Worth of Karen Kaucic is at least $1.11 Million dollars as of 29 September 2020. Ms. Kaucic owns over 20,574 units of PPD Inc stock worth over $396,774 and over the last 5 years she sold PPD stock worth over $715,975. In addition, she makes $0 as Executive Vice President and President of Evidera and Chief Medical Officer at PPD Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Kaucic PPD stock SEC Form 4 insiders trading

Karen has made over 1 trades of the PPD Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 20,574 units of PPD stock worth $715,975 on 29 September 2020.

The largest trade she's ever made was selling 20,574 units of PPD Inc stock on 29 September 2020 worth over $715,975. On average, Karen trades about 4,115 units every 0 days since 2020. As of 29 September 2020 she still owns at least 8,392 units of PPD Inc stock.

You can see the complete history of Ms. Kaucic stock trades at the bottom of the page.

Karen Kaucic biography

Karen Kaucic serves as Executive Vice President and President of Evidera, Chief Medical Officer of the Company. Karen Kaucic has served in various leadership positions at the Company or its predecessor, Jaguar Holding Company I, since December 2009 and currently serves as our executive vice president and president of Evidera, chief medical officer. Prior to joining the Company, Ms. Kaucic held positions in oncology clinical development at AstraZeneca PLC (AZN) from June 2006 to December 2009.

How old is Karen Kaucic?

Karen Kaucic is 60, she's been the Executive Vice President and President of Evidera and Chief Medical Officer of PPD Inc since . There are 1 older and 17 younger executives at PPD Inc. The oldest executive at PPD Inc is Jeffrey Kindler, 64, who is the Independent Director.

What's Karen Kaucic's mailing address?

Karen's mailing address filed with the SEC is C/O PPD, INC., 929 NORTH FRONT STREET, WILMINGTON, NC, 28401.

Insiders trading at PPD Inc

Over the last 21 years, insiders at PPD Inc have traded over $14,532,346,241 worth of PPD Inc stock and bought 130,455 units worth $3,520,800 . The most active insiders traders include Corporate Investors Viii, L..., Corporate Investors Vii, Lt..., and Group Management L.L.C.Carl.... On average, PPD Inc executives and independent directors trade stock every 53 days with the average trade being worth of $124,899,671. The most recent stock trade was executed by Corporate Investors Viii, L... on 8 December 2021, trading 132,841,266 units of PPD stock currently worth $6,309,960,135.

What does PPD Inc do?

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Company's customers include pharmaceutical, biotechnology, medical device, academic and government organization s. With offices in 46 countries and more than 26,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.

Complete history of Ms. Kaucic stock trades at PPD Inc

PPD Inc executives and stock owners

PPD Inc executives and other stock owners filed with the SEC include:

• David Simmons,
  Chairman of the Board, Chief Executive Officer
• William Sharbaugh,
  Chief Operating Officer
• Christopher Scully,
  Chief Financial Officer, Executive Vice President, Treasurer, Assistant Secretary
• Anshul Thakral,
  Executive Vice President, Chief Commercial Officer
• B. Judd Hartman,
  Executive Vice President, Chief Administrative Officer, General Counsel
• Jeffrey Kindler,
  Independent Director
• Colin Hill,
  Independent Director
• Maria Hilado,
  Independent Director
• Tracy Krumme,
  Vice President, Head of Investor Relations
• Stephen Wise,
  Independent Director
• Allen Thorpe,
  Independent Director
• P. Hunter Philbrick,
  Independent Director
• Stephen Ensley,
  Independent Director
• Joe Bress,
  Independent Director
• Glen Donovan,
  Chief Accounting Officer
• Roger Smith,
  Senior Vice President and General Manager of AES
• Karen Kaucic,
  Executive Vice President and President of Evidera, Chief Medical Officer
• David Johnston,
  Executive Vice President - Global Clinical Development
• Christopher Fikry,
  Executive Vice President - Global Laboratory Services
• Ronald Garrow,
  Chief Human Resource Officer, Executive Vice President
• Group Inc.Carlyle Group Man...,
  
• Group Management L.L.C.Carl...,
  
• Jill Pellegrino,
  SVP & General Manager of AES
• Peter Grunebaum,
  Director
• Cecil Mark Brown,
  Sr. VP & CEO
• Charlie Stephen Williamson,
  Chief Financial Officer
• Kathleen Susan Pinson,
  Vice President
• Randy Harp,
  Chief Operating Officer
• Harland Cecil Stonecipher,
  Founder, Chairman of the Board
• Martin H Belsky,
  Director
• John W Hail,
  Director
• Steven Riley Hague,
  Director
• Paid Legal Services Inc Pre,
  Director
• Judd Hartman,
  See Remarks
• Thomas W Smith,
  10% owner
• Corporate Investors Viii, L...,
  
• Julia James,
  EVP, General Counsel,Secretary